UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
The Commanders have a pair of veteran signal-callers behind Daniels on the depth chart. Mariota, a former No. 2 overall ...
Miami’s season is on the precipice after the Hurricanes lost to SMU on the road on Saturday. The loss was UM’s second of the year, and they did it by failing in numerous ways. Here are five takeaways ...
RotoBaller on MSN
Running Back Matchups to Target in Week 9 (2025) - Jonathan Taylor, Christian McCaffrey, Kimani Vidal, More
As we move into the second half of the schedule, the best rushing offenses and worst rushing defenses are becoming a bit more ...
For the market, the end of QT came as liquidity conditions in the Treasury and repo markets began to tighten, with funding stress building. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback